42746 Patient Reported Outcomes in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata

Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2023
This article has no abstract
Epistemonikos ID: 5dc25282fab26b52bb96fd9f8f619f2664dbe872
First added on: Dec 07, 2023